Search Results

Return to List
Results 1–15 of 15
Title Date
1.

Screening for Tay - Sachs Disease

Number 318

(Reaffirmed 2014, Replaces No. 162, November 1995)

ABSTRACT TaySachs disease TSD is a severe progressive neurologic disease that causes death in early childhood Carrier screening should be offered before pregnancy to individuals and couples at high risk including those of Ashkenazi Jewish FrenchCanadian or Cajun descent and those with a family his...

October 2005

PDF Format
2.

Perinatal Risks Associated With Assisted Reproductive Technology

Number 324

(Reaffirmed 2007)

ABSTRACT Over the past two decades the use of assisted reproductive technology ART has increased dramatically worldwide and has made pregnancy possible for many infertile couples A growing body of evidence suggests an association between pregnancies resulting from ART and perinatal morbidity possi...

November 2005

PDF Format
3.

Umbilical Cord Blood Banking

Number 399

(Reaffirmed 2012, Replaces No. 183, April 1997)

ABSTRACT Two types of banks have emerged for the collection and storage of umbilical cord bloodpublic banks and private banks Public banks promote allogenic related or unrelated donation analogous to the current collection of whole blood units in the United States Private banks were initially deve...

February 2008

PDF Format
4.

Direct-to-Consumer Marketing of Genetic Testing

Number 409

Reaffirmed 2014

ABSTRACT Marketing of genetic testing although similar to directtoconsumer advertising of prescription drugs raises additional concerns and considerations These include issues of limited knowledge among patients and health care providers of available genetic tests difficulty in interpretation of g...

June 2008

PDF Format
5.

Ethical Issues in Genetic Testing

Number 410

(Reaffirmed 2014)

ABSTRACT Genetic testing is poised to play an increasing role in the practice of obstetrics and gynecology To assure patients of the highest quality of care physicians should become familiar with the currently available array of genetic tests and the tests limitations Clinicians should be able to ...

June 2008

PDF Format
6.

Spinal Muscular Atrophy

Number 432

Reaffirmed 2014

ABSTRACT Spinal muscular atrophy SMA is an autosomal recessive neurodegenerative disease that results from degeneration of spinal cord motor neurons leading to atrophy of skeletal muscle and overall weakness In current practice patients with a family history of SMA are being offered carrier screen...

May 2009

PDF Format
7.

Preconception and Prenatal Carrier Screening for Genetic Diseases in Individuals of Eastern European Jewish Descent

Number 442

(Reaffirmed 2014, Replaces No. 298, August 2004)

ABSTRACT Certain autosomal recessive disease conditions are more prevalent in individuals of Eastern European Jewish Ashkenazi descent Previously the American College of Obstetricians and Gynecologists recommended that individuals of Eastern European Jewish ancestry be offered carrier screening fo...

October 2009

PDF Format
8.

Carrier Screening for Fragile X Syndrome

Number 469

(Reaffirmed 2014, Replaces No. 338, June 2006)

ABSTRACT Fragile X syndrome is the most common inherited form of mental retardation The syndrome occurs in approximately 1 in 3600 males and 1 in 40006000 females Approximately 1 in 250 females carry the premutation DNAbased molecular analysis is the preferred method of diagnosis for fragile X syn...

October 2010

PDF Format
9.

Family History as a Risk Assessment Tool

Number 478

(Reaffirmed 2015)

ABSTRACT Family history plays a critical role in assessing the risk of inherited medical conditions and single gene disorders Several methods have been established to obtain family medical histories including the family history questionnaire or checklist and the pedigree The screening tool selecte...

March 2011

PDF Format
10.

Update on Carrier Screening for Cystic Fibrosis

Number 486

(Reaffirmed 2014, Replaces No. 325, December 2005)

ABSTRACT In 2001 the American College of Obstetricians and Gynecologists and the American College of Medical Genetics introduced guidelines for prenatal and preconception carrier screening for cystic fibrosis The American College of Obstetricians and Gynecologists Committee on Genetics has updated...

April 2011

PDF Format
11.

Personalized Genomic Testing for Disease Risk

Number 527

(Reaffirmed 2014)

ABSTRACT Advances in genetic technologies have led to the identification of hundreds of single nucleotide polymorphisms that are associated with a variety of complex diseases including cancer diabetes cardiovascular disease and Alzheimer disease Although personalized genomic tests that provide inf...

June 2012

PDF Format
12.

Noninvasive Prenatal Testing for Fetal Aneuploidy

Number 545

ABSTRACT Noninvasive prenatal testing that uses cell free fetal DNA from the plasma of pregnant women offers tremendous potential as a screening tool for fetal aneuploidy Cell free fetal DNA testing should be an informed patient choice after pretest counseling and should not be part of routine pre...

December 2012

PDF Format
13.

Maternal–Fetal Surgery for Myelomeningocele

Number 550

ABSTRACT Myelomeningocele the most severe form of spina bifida occurs in approximately 1 in 1500 births in the United States Fetuses in whom myelomeningocele is diagnosed typically are delivered at term and are treated in the early neonatal period A recent randomized controlled trial found that fe...

January 2013

PDF Format
14.

The Use of Chromosomal Microarray Analysis in Prenatal Diagnosis

Number 581

(Replaces No. 446, November 2009) (See also Practice Bulletin No. 88)

ABSTRACT Chromosomal microarray analysis is a technique that identifies chromosomal abnormalities including submicroscopic abnormalities that are too small to be detected by conventional karyotyping Like conventional fetal karyotyping prenatal chromosomal microarray analysis requires direct testin...

December 2013

PDF Format
15.

Management of Women With Phenylketonuria

Number 636

(Replaces Committee Opinion Number 449, December 2009)

ABSTRACT Phenylketonuria PKU is an autosomal recessive disorder of phenylalanine Phe metabolism characterized by deficient activity of the hepatic enzyme phenylalanine hydroxylase Increased blood Phe levels are toxic to a variety of tissues particularly the developing fetal brain The mainstay of t...

June 2015

PDF Format

American Congress of Obstetricians and Gynecologists
409 12th Street SW, Washington, DC  20024-2188 | Mailing Address: PO Box 70620, Washington, DC 20024-9998